库欣综合征治疗对血脂异常影响的系统综述与荟萃分析
该系统综述与荟萃分析纳入29项观察性或干预性研究,评估库欣综合征治疗对血脂的影响。结果显示治疗显著降低总胆固醇、低密度脂蛋白胆固醇和甘油三酯,高密度脂蛋白胆固醇无显著变化。亚组分析提示肾上腺性高皮质醇血症、使用类固醇合成抑制剂及治疗≥12个月者总胆固醇下降更明显。
要点
- 库欣综合征治疗后总胆固醇、低密度脂蛋白胆固醇和甘油三酯显著下降。
- 高密度脂蛋白胆固醇治疗前后无显著变化。
- 肾上腺性高皮质醇血症、类固醇合成抑制剂及治疗≥12个月者总胆固醇降幅更大。
核心结论
- 库欣综合征治疗后可显著改善血清总胆固醇、低密度脂蛋白胆固醇和甘油三酯水平。
- 高密度脂蛋白胆固醇水平在治疗前后无显著变化。
- 尚需进一步研究明确血脂改善是否直接转化为主要心血管事件风险的降低。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Scopus和EMBASE数据库。
- 共纳入29项观察性或干预性研究,其中51.7%为高质量研究。
- 进行了治疗前后分析及亚组分析。
主要发现
- 总胆固醇平均差异为-26.49(95% CI,-29.95至-23.04;P < .00001)。
- 低密度脂蛋白胆固醇平均差异为-18.44(95% CI,-21.30至-15.57;P < .00001)。
- 甘油三酯平均差异为-17.77(95% CI,-22.70至-12.84;P < .00001)。
- 高密度脂蛋白胆固醇平均差异为-2.34(95% CI,-6.96至2.28;P = .32),无统计学显著性。
- 亚组分析显示肾上腺性高皮质醇血症、使用类固醇合成抑制剂及治疗持续时间≥12个月者总胆固醇下降更明显。
关键数值与推荐
- 总胆固醇平均差异-26.49(95% CI,-29.95至-23.04;P < .00001)。
- 低密度脂蛋白胆固醇平均差异-18.44(95% CI,-21.30至-15.57;P < .00001)。
- 甘油三酯平均差异-17.77(95% CI,-22.70至-12.84;P < .00001)。
- 高密度脂蛋白胆固醇平均差异-2.34(95% CI,-6.96至2.28;P = .32)。
临床怎么用
- 对库欣综合征患者应关注血脂谱,治疗原发病后总胆固醇、低密度脂蛋白胆固醇和甘油三酯可显著改善。
- 治疗持续时间≥12个月、使用类固醇合成抑制剂或肾上腺性高皮质醇血症者血脂改善可能更明显。
- 高密度脂蛋白胆固醇可能不随治疗显著变化,需综合评估心血管风险。
局限性
- 纳入研究为观察性或干预性研究,可能存在异质性和混杂偏倚。
- 仅51.7%的研究被评为高质量。
- 血脂改善是否转化为主要心血管事件风险降低尚不明确,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Cushing syndrome (CS) is a clinical condition caused by increased plasma cortisol levels and characterized by high cardiovascular mortality. Among the metabolic effects of CS and its treatment, glycemic disturbances have been investigated in depth, while data on dyslipidemia is still lacking. OBJECTIVES: Our study aims at evaluating the effects of CS treatment on serum lipid levels. MATERIALS AND METHODS: A literature search was conducted using PubMed, Scopus, and EMBASE databases to investigate the effects of CS treatment on serum total cholesterol (TC), low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides. Before-after analysis and subgroup analysis were performed. RESULTS: Twenty-nine observational or interventional studies (51.7% of good quality) were included in the quantitative analysis. Treatment of CS led to clinically and statistically significant decrease in serum TC (mean difference [MD] -26.49; 95% CI, -29.95 to -23.04; P < .00001), low-density lipoprotein cholesterol (MD -18.44; 95% CI, -21.30 to -15.57; P < .00001), and triglycerides levels (MD -17.77; 95% CI, -22.70 to -12.84; P < .00001), with no significant changes in high-density lipoprotein cholesterol levels (MD -2.34; 95% CI, -6.96 to 2.28; P = .32). Subgroup analysis showed greater decrease in TC levels in subjects with adrenal hypercortisolism, in those treated with steroidogenesis inhibitors, and in those with treatment duration ≥12 months. In addition, CS treatment significantly decreased blood glucose levels, body mass index, waist circumference, and insulin resistance index. CONCLUSION: Our study demonstrates a significant improvement in serum lipid levels after treatment of CS. Because the cardiovascular complications of hypercortisolism depend on several factors, further studies are needed to determine whether this directly translates into an adequate reduction in the risk of major cardiovascular events.
引用
- Salvio G, Ciarloni A, Aboud N, et al. The effect of hypercortisolism treatment on dyslipidemia in Cushing syndrome: systematic review and meta-analysis. J Clin Endocrinol Metab. 2026. PMID: 41432529. doi:10.1210/clinem/dgaf681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。